East Ocyon Bio

East Ocyon Bio is an Indian biotechnology company focused on developing next-generation cell and gene therapies for cancer, autoimmune disorders, and rare diseases. The company specializes in allogeneic, off-the-shelf cellular immunotherapies using immune cells such as Natural Killer (NK) cells and Gamma Delta T (γδ T) cells. Its proprietary technology platforms are designed to enhance the ability of these immune cells to recognize and eliminate tumor cells while addressing limitations associated with conventional patient-specific (autologous) cell therapies. East Ocyon Bio is developing CAR-NK and CAR-γδ T-cell therapies targeting solid tumors and hematological malignancies, with the objective of creating scalable and potentially more accessible treatment options. The company combines cell engineering, gene therapy, molecular biology, and advanced bioprocessing capabilities to develop its therapeutic pipeline. Its research areas also include mRNA and gene therapy technologies. The company is building GMP-ready manufacturing capabilities to support the development and eventual commercialization of its cellular therapies. Its vision is to develop curative allogeneic cell therapies in India and make them available to patients in India and global markets simultaneously, with a focus on affordability, quality, and timely access. East Ocyon Bio aims to contribute to the advancement of India's cell and gene therapy ecosystem by translating innovative immunotherapy research into scalable clinical and commercial solutions.